» Articles » PMID: 36305053

Association of Plasma Bone Morphogenetic Protein-4 Levels with Arterial Stiffness in Hypertensive Patients

Overview
Journal J Clin Lab Anal
Publisher Wiley
Date 2022 Oct 28
PMID 36305053
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Arterial stiffness interacts with hypertension, becoming an early marker of hypertension-mediated target organ damage. This study aimed to assess the association between plasma concentrations of bone morphogenetic protein-4 (BMP-4) and arterial stiffness during hypertension.

Methods: Using cardio-ankle vascular index (CAVI) to determine arterial stiffness status, 204 individuals with essential hypertension were classified into two groups, high CAVI (abnormal) group (n = 94) and low (normal) CAVI group (n = 110). Data were collected including clinical characteristics and laboratory measurements. Plasma levels of BMP-4 were tested by using ELISA analysis.

Results: Plasma levels of BMP-4 were substantially greater in high CAVI group than that in low CAVI group [38.51 (31.79-50.83) pg/mL vs. 31.15 (29.38-32.37) pg/mL; p < 0.001]. As shown by spearman correlation analysis, BMP-4 concentrations were correlated with CAVI values in hypertensive individuals (r = 0.406, p < 0.001). After adjustment for potential confounders, elevated BMP-4 levels were related with high CAVI (OR, 1.070; 95% CI, 1.003-1.108; p < 0.001). The best BMP-4 cutoff value for identifying high CAVI, as determined by ROC curve analysis, was 33.34 pg/mL (AUC, 0.751; 95% CI, 0.683-0.818; p < 0.001).

Conclusion: Plasma levels of BMP-4 are increased in hypertensive individuals with high CAVI. Elevated BMP-4 levels are strongly correlated with higher CAVI values, implying a predictive value of BMP-4 in arterial stiffness during hypertension.

Citing Articles

Plasma Biomarkers for Hypertension-Mediated Organ Damage Detection: A Narrative Review.

Liu X, Yang M, Lip G, McDowell G Biomedicines. 2024; 12(5).

PMID: 38791032 PMC: 11118189. DOI: 10.3390/biomedicines12051071.


Association of plasma bone morphogenetic protein-4 levels with arterial stiffness in hypertensive patients.

Wang N, Guo Y, Dong Y, Li X, Liu Q, Liu Q J Clin Lab Anal. 2022; 36(11):e24746.

PMID: 36305053 PMC: 9701857. DOI: 10.1002/jcla.24746.

References
1.
Garaikoetxea M, Martin-Nunez E, Navarro A, Matilla L, Fernandez-Celis A, Arrieta V . Targeting Fatty Acid-Binding Protein 4 Improves Pathologic Features of Aortic Stenosis. Int J Mol Sci. 2022; 23(15). PMC: 9369247. DOI: 10.3390/ijms23158439. View

2.
Cai J, Pardali E, Sanchez-Duffhues G, Ten Dijke P . BMP signaling in vascular diseases. FEBS Lett. 2012; 586(14):1993-2002. DOI: 10.1016/j.febslet.2012.04.030. View

3.
Miriyala S, Gongora Nieto M, Mingone C, Smith D, Dikalov S, Harrison D . Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation. 2006; 113(24):2818-25. DOI: 10.1161/CIRCULATIONAHA.106.611822. View

4.
Stahls 3rd P, Lightell Jr D, Moss S, Goldman C, Woods T . Elevated serum bone morphogenetic protein 4 in patients with chronic kidney disease and coronary artery disease. J Cardiovasc Transl Res. 2012; 6(2):232-8. PMC: 3594471. DOI: 10.1007/s12265-012-9429-9. View

5.
Sarer Yurekli B, Unal Kocabas G, Aksit M, Ozdemir Kutbay N, Suner A, Yurekli I . The low levels of bone morphogenic protein-4 and its antagonist noggin in type 2 diabetes. Hormones (Athens). 2018; 17(2):247-253. DOI: 10.1007/s42000-018-0041-5. View